Technical Note: The Effect of Alcoholic Beverages on Sustained Release - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Technical Note: The Effect of Alcoholic Beverages on Sustained Release
The authors evaluated the effect of alcoholic beverages on the release profiles of sustained-release dosage forms containing metformin and diclofenac.


Pharmaceutical Technology
Volume 34, Issue 12, pp. 47-49


Table I: F2 values of dissolution data.
The significant changes in release pattern are further confirmed by low F2 values. The similarity factor F2, as defined by the US Food and Drug Administration, is a logarithmic reciprocal square-root transformation of one plus the mean squared (i.e., the average sum of squares) differences of drug percent dissolved between the test and reference products (5). Table I compares the F2 values for all dissolutions in alcoholic beverages with those in water. The results clearly indicate the effect of alcoholic beverages on in vitro drug release.

Conclusion

The authors concluded that the release of the instant-release formulations was faster in Kingfisher Strong beer, Mild beer, rum, and 40% alcohol than it was in water. The difference may be attributable to the volume of the alcoholic beverages, rather than to their strength. The drug release of the sustained-release formulations was faster in 40% alcohol and in rum than it was in water. The authors concluded that the consumption of alcoholic beverages should be avoided during treatment with sustained-release formulations of metformin and diclofenac to prevent dose dumping.

Anagha Joshi* is a doctoral student at Bharati Vidyapeeth University's Poona College of Pharmacy and assistant professor of pharmaceutical chemistry at Indira College of Pharmacy, Pune, Maharashtra, India,
. Shivajirao S. Kadam is vice-chancellor of Bharati Vidyapeeth University Pune, Maharashtra,India, and Aatmaram P. Pawar is a professor of pharmaceutics at Bharati Vidyapeeth University Pune, Maharashtra, India.

*To whom all correspondence should be addressed.

Submitted: Feb. 13, 2010. Accepted: Apr. 5, 2010.

References

1. L.A. Bennett et al., Alcohol Health Res. World 22 (4), 243–252 (1998).

2. R.J. Meyer and A.S. Hussain, Proceedings of FDA's Advisory Committee For Pharmaceutical Science meeting (Rockville, MD, 2005), p. 2.

3. Indian Pharmacopoeia (Controller of Publications, New Delhi, India, 2007), p. 1020.

4. Goodman and Gilman's The Pharmacological Basis of Therapeutics, J.G. Hardman, L.E. Limbird, and A.G. Gilman, Eds. (McGraw-Hill, New York, 10th ed., 2001), pp. 644–646.

5. M.C. Gohel and M.K. Panchal, Dissol. Technol. 9 (1), 1–5 (2002).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here